目的 评价舒肝解郁胶囊联合帕罗西汀治疗精神分裂症后抑郁的治疗效果。方法 采用随机方法将100例精神分裂症后抑郁患者分为治疗组(舒肝解郁胶囊与帕罗西汀合用)和对照组(单用帕罗西汀)各50例。两组患者口服帕罗西汀初始剂量为10～20 mg/d, 逐渐加至20～40 mg/d。治疗组在应用帕罗西汀的同时, 加服舒肝解郁胶囊1.44 g/d, 疗程8周。分别在治疗前及治疗2、4、8周后采用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)对两组患者进行疗效及不良反应评定。结果 治疗2、4、8周后两组HAMD评分均比治疗前明显下降, 且治疗组评分显著低于对照组(P<0.05)。TESS评分两组间差异无显著性。治疗组的显效率90%显著高于对照组的显效率74%(P<0.05)。结论 舒肝解郁胶囊联合帕罗西汀治疗精神分裂症后抑郁疗效好于单用帕罗西汀治疗, 未见不良反应增加。
Objective To compare the effect of Shugan Jieyu Capsule plus Paroxetine in the treatment of past-schizophrenia depression. Methods One hundred patients with past-schizophrenia depression were randomly divided into a study group (treated with Shugan Jieyu Capsule plus Paroxetine) and a control group (treated with Paroxetine only) equally. The treatment course is 8 weeks. At first, the initial dose of Paroxetine was 10—20 mg/d, gradually increased to 20—40 mg/d. At the same time, the patients in the study groups were added to take Shugan Jieyu Capsule 1.44g/d. When the patients were grouped, evaluating the patients in two groups in the aspects of the clinical effect and side effects with Hamilton's depression scale (HAMD) and treatment emergent symptom scale (TESS). In addition, after 2, 4, and 8 weeks, the patients in the aspects of the clinical effect and side effects with HAMD and TESS were re-evaluated. Results After 2, 4, and 8 weeks, the HAMD scores of patients in both groups were more significantly decreased than the beginning, and the scores of the patients in the study group were lower than those of the patients in the control group (P<0.05). The TESS scores between the two groups had no significant difference (P>0.05). The study group showed the effective rate of 90% which was significantly higher than 74% of the control group (P<0.05). Conclusion Shugan Jieyu Capsule plus Paroxetine has better effect in the treatment of past-schizophrenia depression, the adverse reaction is not increasing.